The HistoCheck 1 software is offered as a tool 'that is capable of assessing the allogenicity (matching score) between any pair of clinically relevant HLA class Iy alleles'. This is a brave attempt to aid Transplant Physicians in making the often difficult choice between two or more mismatched (unrelated) donors, when no completely matched donor is available. This internet-based software provides a score that takes into account both the functional and the structural difference between two HLA alleles at one locus. The predictive value of HistoCheck is based on the presumption that transplant success is improved by selecting a donor with an HLA type most similar to the patient.
Although there are limited data published to suggest transplants with allele mismatches fare better than antigenic mismatches, 2 our knowledge of the biology of HLA suggests that limited polymorphic differences are unlikely to be significantly less immunogenic than numerous differences. This is because limited polymorphisms are not functionally null. Polymorphism is focused at residues that line the peptide-binding groove and at the surface recognised by T-cell receptors. Thus, HLA variants confer a phenotyping change presumed to provide a selective advantage in the fight against invading pathogens. 3 We know small differences between MHC molecules influence T-cell recognition. Indeed, prior to DNA sequencing, serologically defined groups of related HLA variants were subdivided on the basis of their differential reactivity with alloreactive T cells. 4, 5 The report describing bone marrow transplant rejection induced by a single amino-acid variant demonstrates that small differences are sufficient for development of in vivo alloreactivity. 6 It has even been suggested that limited differences may induce stronger alloresponses than numerous differences 7, 8 because the foreign MHC molecule closely resembles self-MHC and is therefore more likely to crossreact with self-educated T cells. The impact of qualitative differences is contentious.
In this context, at the Anthony Nolan Trust we are often asked to recommend the 'best' donor, for an individual patient, after a search has been carried out. The HLA mismatch in these situations could be assessed using HistoCheck. However, as yet there are no clinical data provided by the authors to test the validity of the scores given by this software. In order to test the predictive value of the sequence-similarity matching (SSM) scores on transplantation outcome, we analysed this score in conjunction with the clinical data in 26 single HLA-A allele mismatched recipients from our clinical database (matched for HLA-B, -C, -DRB1, -DQB1 at allele level, matching at DPB1 was not essential). These pairs form part of a larger database held at the Anthony Nolan Trust. Ethical permission was obtained. The 26 pairs had all received an unrelated donor transplant for a malignant disease.
Each HLA-A mismatch was entered into the HistoCheck algorithm and had an SSM score assigned ( Table 1) . The SSM scores ranged from 0.88 to 30.39 with a mean of 10.16 (median of 9.64) and a mode of 2.90. With few exceptions, predictably, the lower scores were in pairs mismatched at an allelic level and the higher scores in antigenic mismatches. The clinical outcome was then correlated to the SSM score ( Table 2 ). The overall survival in this cohort (mean follow-up ¼ 400 days, median ¼ 282 days; range 14-1482) was 42% (11/26). Three of the recipients failed to achieve neutrophil engraftment. Acute graft-versus-host disease (aGvHD) data were available in 24 patients. Of these, 62% were reported to develop aGvHD. This complication was seen in those with high as well as low scores. The grade of aGvHD was II-IV in five cases. Three of those with grade II-III aGvHD had 'lower' scores, while two had 'higher' scores. In those eligible for this analysis, the incidence of chronic GvHD (cGvHD) was 38%. As with aGvHD, this complication was found in both the low and high scoring pairs and was extensive in four cases (UPN 4, 14, 20 and 24). The incidence of disease relapse was 50%. It appears that those with lower scores tend to suffer more disease relapse, although this is not seen in all cases. Likewise, none of those with a score above 13 suffered relapse of their disease. In addition, those with lower scores tended to be more likely to die from relapse, while this cause was less likely at the higher scores.
To ascertain whether these SSM scores could be applied with equal weight to each locus, we also looked at the outcome in nine single HLA-B allele mismatched pairs. The scores here were all low as compared to the scores at HLA-A (ranging between 0.4 and 4.38; median 1.42, mean 1.85). Of note, all but one of the mismatches were allelic (the likely reason for this being that antigenic HLA-B mismatched pairs usually have associated HLA-C mismatches and thus were excluded from this analysis). Although all achieved neutrophil engraftment, all but one of these patients had died at the time of analysis. In addition five had developed aGvHD (55%), in four greater than grade I disease.
Therefore, our small test suggests there is no obvious benefit to patients who received bone marrow transplants from HLA mismatched donors with low HistoCheck scores. Experimental studies are required to assess whether there are definable and consistent differences in the strength of the alloresponse induced by specific HLA mismatches. In addition, clinical studies of large numbers of transplant patients are needed to determine whether qualitative differences influence transplant success.
In the absence of this information, we believe it is premature to begin to select donors on the basis of low HistoCheck scores. It is essential that clinicians understand the limitations of this software and we urge great caution in using SSM scores as part of the selection process between mismatched unrelated donors. BE Shaw LD Barber JA Madrigal S Cleaver SGE Marsh
